The global preimplantation genetic testing market was estimated to be valued at USD 802.2 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2030. The increasing prevalence of single-gene, mitochondrial, and other genetic disorders is expected to drive the demand for preimplantation diagnosis and screening processes in the coming years. According to the Florida Department of Health, approximately one in every 33 babies born in the U.S. is affected by a congenital disability, which translates to nearly 120,000 affected infants each year. With the introduction of new testing options, demand for preimplantation genetic testing is anticipated to rise. For example, in July 2023, Thermo Fisher Scientific Inc. launched two tests based on next-generation sequencing (NGS) specifically for preimplantation genetic testing for aneuploidy (PGT-A).

Preimplantation genetic diagnosis (PGD) is a procedure utilized prior to in vitro fertilization (IVF) to enhance the chances of a successful pregnancy. PGD is commonly used in IVF cycles for women who have faced multiple miscarriages or have had previous pregnancies involving chromosomal abnormalities. This method is particularly advantageous for couples at risk of hereditary disorders, contributing positively to market growth.

The incorporation of aneuploidy screening within PGD has notably improved the outcomes of IVF procedures. Aneuploidy testing in IVF clinics enables the identification of abnormal embryos, which in turn leads to higher success rates for pregnancies. Preimplantation genetic testing for aneuploidy (PGT-A) assesses embryos for chromosomal abnormalities, ensuring that the correct number of chromosomes is present. The benefits of PGT-A, such as increased likelihood of pregnancy, lower miscarriage rates, and fewer IVF cycles required to achieve a successful pregnancy, are expected to further enhance the adoption of these tests throughout the forecast period.

Gather more insights about the market drivers, restrains and growth of the Preimplantation Genetic Testing Market

Drivers, Opportunities & Restraints

The increasing incidence of genetic diseases has significantly boosted the demand for preimplantation genetic testing (PGT). As the prevalence of genetic disorders rises, PGT has become essential in in vitro fertilization (IVF) procedures. This type of testing plays a crucial role in identifying and preventing the transfer of genetic abnormalities, thereby enhancing the likelihood of successful pregnancies. Innovations such as preimplantation genetic testing for aneuploidy (PGT-A) and monogenic diseases (PGT-M) have further improved clinical outcomes, leading to reduced miscarriage rates and a lower risk of hereditary conditions. As a result, the adoption of PGT is expected to grow, driven by its effectiveness in detecting and managing genetic disorders.

Additionally, the rising rate of infertility has significantly contributed to the increasing demand for PGT in assisted reproductive technologies (ART). Infertility affects millions of individuals worldwide, with contributing factors such as delayed childbearing, lifestyle changes, environmental influences, and underlying health conditions playing critical roles. As more couples seek solutions for infertility, in vitro fertilization has become a prominent method for achieving pregnancy. Within the IVF framework, PGT is vital, ensuring the selection of genetically healthy embryos for implantation, which in turn enhances the chances of a successful pregnancy.

Preimplantation genetic testing, encompassing both PGT-A and PGT-M, assists in identifying chromosomal abnormalities and specific genetic disorders in embryos prior to implantation. This capability not only increases the likelihood of achieving a successful pregnancy but also minimizes the risks of miscarriage and genetic disorders in future offspring. The ability of PGT to screen for genetic issues before pregnancy provides reassurance to couples facing infertility, offering better outcomes and reducing the number of cycles required to achieve pregnancy. Furthermore, advancements in testing technologies have significantly improved the accuracy and reliability of PGT, which is driving its increased adoption. As infertility rates continue to climb, the utilization of PGT within ART is expected to expand, providing hope and viable solutions for those struggling with infertility.

Order a free sample PDF of the Preimplantation Genetic Testing Market Intelligence Study, published by Grand View Research.